ELITE Regulatory Tuesday, August 4, 2026 +0.10 Neutral

Elite Pharmaceuticals Launches Generic Requip XL

Elite Pharmaceuticals announced the U.S. commercial launch of its generic Requip XL tablets, a non-ergoline dopamine agonist used to treat Parkinson's disease. The product offers a competitive entry into a market with $10 million in annual branded sales.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day